Study participant characteristics at enrolment
| Variation | Total (n=133) | Cohort, median (IQR) | P value | |
| miR-219-5p <1.50 (n=66) | miR-219-5p ≥1.50 (n=67) | |||
| Age (years) | 64 (58–70) | 65 (59–70) | 63 (56.5–68) | 0.276 |
| BMI (kg/m2) | 23.12±3.09 | 22.99±3.22 | 23.26±2.98 | 0.619 |
| Serum CEA level (ng/mL) | 3.43 (1.96–9.26) | 3.34 (1.92–10.05) | 3.43 (1.99–8.11) | 0.87 |
| Serum CRP level (μmol/L) | 7.83 (1.68–12.78) | 10.68 (2.78–13.15) | 5.64 (1.2–12.16) | 0.107 |
| Albumin level (g/L) | 39.46±5.2 | 38.86±4.68 | 40.05±5.65 | 0.188 |
| Neutrophil count (×109/L) | 4.55 (3.59–5.88) | 4.54 (3.77–5.75) | 4.55 (3.48–5.92) | 0.975 |
| Lymphocyte count (×109/L) | 1.63 (1.31–1.95) | 1.5 (1.21–1.78) | 1.73 (1.38–2.08) | 0.031* |
| Haemoglobin level (g/L) | 133 (125–145) | 134 (124–145) | 132 (125–143.5) | 0.564 |
| Platelet count (×109/L) | 233 (184–288) | 244.5 (180–293.75) | 226 (184.5–273.5) | 0.306 |
| PNI score | 47.9 (43.95–51.85) | 45.98 (42.51–50.38) | 48.7 (44.92–54) | 0.026* |
| NLR | 2.66 (1.99–4.19) | 2.75 (2.11–4.57) | 2.59 (1.92–3.7) | 0.232 |
| Gender, n (%) | 0.211 | |||
| Female | 27 (20) | 10 (15) | 17 (25) | |
| Male | 106 (80) | 56 (85) | 50 (75) | |
| Metastasis, n (%) | 0.299 | |||
| No | 45 (34) | 19 (29) | 26 (39) | |
| Yes | 88 (66) | 47 (71) | 41 (61) | |
| Stage of SCLC | 0.038* | |||
| Limited disease | 51 (38) | 19 (29) | 32 (48) | |
| Extensive disease | 82 (62) | 47 (71) | 35 (52) | |
| Immunotherapy, n (%) | 0.197 | |||
| No | 108 (81) | 57 (86) | 51 (76) | |
| Yes | 25 (19) | 9 (14) | 16 (24) | |
| Radiation therapy, n (%) | 0.417 | |||
| No | 79 (59) | 42 (64) | 37 (55) | |
| Yes | 54 (41) | 24 (36) | 30 (45) | |
| Use of platinum, n (%) | 0.244 | |||
| No | 2 (2) | 2 (3) | 0 (0) | |
| Yes | 131 (98) | 64 (97) | 67 (100) | |
| Chemotherapy | 0.45 | |||
| AP | 28 (21) | 12 (18) | 16 (24) | |
| DP | 15 (11) | 6 (9) | 9 (13) | |
| EP | 71 (53) | 35 (53) | 36 (54) | |
| GP | 3 (2) | 2 (3) | 1 (1) | |
| Others | 16 (12) | 11 (17) | 5 (7) | |
| Target therapy, n (%) | 0.627 | |||
| No | 116 (87) | 59 (89) | 57 (85) | |
| Yes | 17 (13) | 7 (11) | 10 (15) | |
| Use of TKI, n (%) | 0.449 | |||
| No | 118 (89) | 60 (91) | 58 (87) | |
| TKI I | 9 (7) | 4 (6) | 5 (7) | |
| TKI II | 1 (1) | 1 (2) | 0 (0) | |
| TKI III | 5 (4) | 1 (2) | 4 (6) | |
| Use of VEGF inhibitor, n (%) | 0.645 | |||
| No | 114 (86) | 58 (88) | 56 (84) | |
| Yes | 19(14) | 8 (12) | 11(16) | |
| KPS score, n (%) | 0.678 | |||
| 40 | 2 (2) | 0 (0) | 2 (3) | |
| 50 | 5 (4) | 3 (5) | 2 (3) | |
| 60 | 7 (5) | 3 (5) | 4 (6) | |
| 70 | 12 (9) | 8 (12) | 4 (6) | |
| 80 | 29 (22) | 14 (21) | 15 (22) | |
| 90 | 56 (42) | 29 (44) | 27 (40) | |
| 100 | 22 (17) | 9 (14) | 13 (19) | |
| Smoking, n (%) | 0.255 | |||
| No | 51 (38) | 29 (44) | 22 (33) | |
| Yes | 82 (62) | 37 (56) | 45 (67) | |
| Hypertension, n (%) | 1 | |||
| No | 80 (60) | 40 (61) | 40 (60) | |
| Yes | 53 (40) | 26 (39) | 27 (40) | |
| Diabetes, n (%) | 1 | |||
| No | 116 (87) | 58 (88) | 58 (87) | |
| Yes | 17 (13) | 8 (12) | 9 (13) | |
| Hyperlipaemia, n (%) | 0.579 | |||
| No | 120 (90) | 61 (92) | 59 (88) | |
| Yes | 13 (10) | 5 (8) | 8 (12) | |
| Heart failure, n (%) | 1 | |||
| No | 130 (98) | 65 (98) | 65 (97) | |
| Yes | 3 (2) | 1 (2) | 2 (3) | |
| ACS, n (%) | 0.619 | |||
| No | 129 (97) | 65 (98) | 64 (96) | |
| Yes | 4 (3) | 1 (2) | 3 (4) | |
***P<0.001, **p<0.01, *p<0.05.
ACS, acute coronary syndrome; AP, doxorubicin/cisplatin; BMI, body mass index; CEA, carcinoembryonic antigen; CRP, C reactive protein; DP, dipyridamole; EP, etoposide/cisplatin; GP, gemcitabine/cisplatin; KPS, Karnofsky Performance Status; NLR, neutrophil–lymphocyte ratio; PNI, prognostic nutritional index; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.